triple glp 1 Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor agonist GLP-1-based therapies for type 2

Synthesis and characterization

Less common side effects include diarrhea and fatigue

Physiology 21, 362369

Alternative and non-mutually exclusive mechanisms may involve favorable effects on basal energy expenditure [57] or on the choice of less energy-rich foods consumed in free-living conditions [58], although these latter hypotheses remain to be validated in clinical studies

The FDA has not approved phentermine for concurrent use with GLP-1 agonists, and labeling for both agents includes warnings against unrecommended combinations

Gorski P & Tarkowski M (1992) Non specific environmental factors and asthma development